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ABSTRACT  
Introduction  
Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist 
(LABA) are the preferred long-term treatment for adults and adolescents with symptomatic 
asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline 
and the long-acting muscarinic antagonist (LAMA) tiotropium (approved in 2015). There is a 
need for more effective therapies, as many patients continue to have poorly controlled asthma. 
Areas covered 
New and developing long-acting non-adrenoreceptor synthetic drugs for the treatment of 
symptomatic chronic asthma despite treatment with an ICS alone or combined with a LABA. 
Data was reviewed from studies published up until November 2016. 
Expert opinion  
Tiotropium improves lung function and has a modest effect in reducing exacerbations when 
added to ICS alone or ICS and LABA. The LAMAs umeclidinium and glycopyrronium are under 
development in fixed dose combination with ICS and LABA. Novel small molecule drugs, such as 
CRTH2 receptor antagonists, PDE4 inhibitors, protein kinase inhibitors and nonsteroidal 
glucocorticoid receptor agonists and ‘off-label’ use of licensed drugs, such as macrolides and 
statins are under investigation for asthma, although their effectiveness in clinical practice is not 
established. To better achieve the goal of developing effective novel small molecule drugs for 
asthma will require greater understanding of mechanisms of disease and the different 
phenotypes and endotypes of asthma.  
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1. INTRODUCTION 
 
Asthma is a chronic inflammatory disease of the airways that affects over 300 million people 
worldwide, of whom 80% are adults and adolescents. The Global Initiative for Asthma (GINA) 
guideline for the pharmacological treatment of adults and adolescents with asthma 
recommends a step-wise approach to control symptoms and minimize future risk (Figure 1) 1. 
Daily low dose inhaled corticosteroid (ICS) is the preferred treatment option for mild persistent 
asthma 1, 2 as ICS improves asthma control and lung function as well as reduces the risk of 
exacerbations and death 3, 4. At step 3, the combination of low dose ICS and inhaled long-acting 
beta2-agonist (LABA) is recommended. The safety of LABAs for the treatment of asthma has 
been a major focus for discussion, although recent new research has provided reassurance that 
LABAs can be used safely in combination with ICS 5, 6. Alternative less effective add-on options 
to a LABA are leukotriene-receptor antagonists and low dose theophylline 7. At Step 4, the 
combination of a medium dose ICS and LABA plus as-needed short-acting beta2-agonist or low 
dose ICS and formoterol combination as maintenance and reliever treatment are 
recommended as first-line options. Add-on therapies for patients with uncontrolled asthma 
despite using the combination of a medium or high dose ICS and LABA are leukotriene-receptor 
antagonists and sustained-release theophylline, although evidence for their efficacy is based on 
clinical trials in patients receiving ICS alone and not when combined with a LABA. The long-
acting muscarinic antagonist (LAMA) tiotropium was included in the 2015 GINA guideline as an 
alternative add-on therapy for people with a history of exacerbations. After assessment by a 
specialist, add-on therapies at step 5 include tiotropium, monoclonal antibodies mepolizumab 
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and omalizumab and low dose oral corticosteroid. The 2016 British Guideline on the 
management of asthma recommendations on pharmacological treatment are broadly similar to 
those advocated in the GINA guideline, although the British guideline no longer refers to 
numerical steps of treatment and uses descriptive terms only for each step 8.  
 
Despite the use of current therapies, surveys indicate that many patients have poorly controlled 
symptoms and experience frequent exacerbations 9, 10.  Poor asthma control can be due to 
factors other than uncontrolled disease, such as poor inhaler technique, non-adherence to drug 
treatment and co-morbidities, and these issues should be identified and managed before 
adding further treatment. For some individuals, particularly those with severe disease, there is 
an unmet need for improved therapies. This reviews summarizes the efficacy and safety of new 
long-acting non-adrenoreceptor synthetic drugs currently used in the clinic or that are under 
clinical development for patients with poorly controlled chronic asthma despite treatment with 
ICS alone or combined with a LABA (Table 1). Evidence is obtained from key clinical therapeutic 
phase III trials, selected phase II trials and studies in ‘real-life’ populations that were published 
predominately in the last five years. 
 
2. LONG-ACTING MUSCARINIC ANTAGONISTS 
 
Long-acting muscarinic antagonists (LAMA) competitively inhibit the action of endogenously 
released acetylcholine at muscarinic (M)3 receptors on airway smooth muscle resulting in 
prolonged bronchodilation. Additionally, LAMAs may reduce mucus secretion by inhibition of 
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M3 receptors on submucosal glands and attenuate inflammation by antagonism of muscarinic 
receptors on inflammatory cells 11. Antagonising autoinhibitory M2 receptors on vagal nerve 
terminals could potentially enhance acetylcholine release and thereby increase airway smooth 
muscle contraction 12, however,  slow dissociation of LAMAs from the M3 receptor compared 
with the M2 receptor preventing LAMAs causing bronchoconstriction 12.  The LAMAs aclidinium, 
glycopyrronium, tiotropium and umeclidinium are approved for the treatment of COPD 13, 
whereas tiotropium is the only LAMA currently licensed for the treatment of asthma. 
Tiotropium (Respimat® SoftMist inhaler) 5 μg daily dose was approved for use in the European 
Union in 2014 as add-on therapy to maintenance ICS (>800 μg budesonide or equivalent) plus 
LABA, in patients aged 18 years who experienced one or more severe asthma exacerbations in 
the previous year. The Tiotropium Respimat® 2.5 μg daily dose was approved by the US Food 
and Drug Administration in 2015 for once-daily maintenance treatment of asthma in patients 
aged 12 years or older. Other countries including Australia, Canada and Japan have approved 
tiotropium for use in asthma. 
 
2.1 Tiotropium add-on to low and medium dose ICS 
 
A Cochrane systematic review (5 trials, 2563 participants) evaluated the efficacy and safety of 
adding a LAMA to any dose of an ICS in adults whose asthma was not well controlled by the 
same dose of ICS and who were not taking a LABA 14. The addition of tiotropium resulted in 35% 
reduction in severe exacerbations (odds ratio (OR) 0.65, 95%CI 0.46 to 0.93; 2277 participants; 
four studies) and an increase in trough forced expiratory volume in 1 second (FEV1) (140 ml), 
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but no improvement in asthma control or quality of life scores. The review was not able to 
conclude whether there were benefits of tiotropium add-on in hospital admissions and all-
cause serious adverse events due to the infrequency of these events. Two phase III trials have 
examined the effects of tiotropium in adolescents with asthma. A 48-week phase III, 
randomized controlled trial assessed the efficacy and safety of once-daily tiotropium 5 μg or 2.5 
μg added to ICS with or without a leukotriene receptor antagonist in 398 adolescents patients 
aged 12 to 17 years with moderate symptomatic asthma 15. Tiotropium produced 
improvements in the primary end-point, peak FEV1 at 24 weeks (174 ml 95% CI, 76-272 ml) 
compared with placebo, whereas asthma control questionnaire (ACQ) and asthma quality of life 
questionnaire (AQLQ) scores were not significantly improved with tiotropium. A 12-week phase 
III trial assessed the efficacy and safety of once-daily tiotropium 5 μg added to ICS plus one or 
more controller therapies in 392 adolescents with severe symptomatic asthma 16 and found no 
significantly improvement in peak FEV1 or ACQ score compared with placebo 16.  
 
2.2 Tiotropium add-on compared with doubling the dose of ICS  
 
A Cochrane systematic review (1 trials, 210 participants) evaluated the efficacy and safety of 
adding a LAMA to any dose of an ICS compared with increasing the dose of ICS in adults whose 
asthma was not well controlled 17. The review included one cross-over trial of 14 weeks 
duration 18. The addition of tiotropium 18 μg once daily (dry powder suspension) compared to 
doubling low to medium dose of ICS resulted in a significant improvement in the primary 
outcome, morning peak expiratory flow (PEF) and non-significant reduction in a secondary 
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outcome, severe exacerbations (OR 0.57, 95% CI 0.22 to 1.43). The addition of tiotropium 
resulted in an increase in FEV1 (100 ml) and slight decrease in ACQ score. . Overall, the authors 
of the systematic review concluded it was not possible to know whether adding tiotropium to 
ICS is more effective or safer than increasing the dose of ICS 17. 
 
2.3 Tiotropium add-on compared with LABA 
 
Two 24-week, replicate phase III randomized, controlled trials compared the effects on peak 
and trough FEV1 response and ACQ-7 score of daily tiotropium 5 μg or 2·5 μg, twice-daily 
salmeterol 50 μg, or placebo in 1972 participants with symptomatic asthma and a pre-
bronchodilator FEV1 of 60 to 90% predicted despite use of medium-dose inhaled ICS 19. The 
addition of once daily tiotropium improved lung function and asthma control to a similar extent 
as twice daily salmeterol. A Cochrane systematic review (4 trials, including the two replicate 
trials described above 19, approximately 2000 participants) evaluated the efficacy and safety of 
adding a LAMA (tiotropium) to ICS compared with adding a LABA (salmeterol) for adults whose 
asthma not well controlled on ICS alone 20. The studies were up to 24 weeks in duration. Severe 
exacerbations were similar in the two treatment groups (OR 1.05, 95%CI 0.50 to 2.18; 1753 
participants; 3 studies). Trough FEV1 was slightly higher in the LAMA group compared to LABA 
group (50 ml, 95% CI 10 to 90; 1745 participants, 4 studies). ACQ and AQLQ scores were slightly 
worse with LABA. Adverse events on LAMA were slightly higher, but the difference with LABA 
was not statistically significant. Overall, the authors concluded that the evidence was not 
sufficient to advocate LAMA as an alternative for LABA as add-on therapy. 
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2.4 Tiotropium add-on to medium and high dose ICS and LABA 
 
Two replicate phase III randomized, controlled trials compared the effects on lung function and 
exacerbations of tiotropium 5 μg or placebo, both delivered by a soft-mist inhaler once daily for 
48 weeks, as an add-on to high-dose ICS (≥800 μg budesonide or the equivalent) plus a LABA in 
912 adult patients with severe symptomatic asthma 21. All participants had chronic airflow 
obstruction (post-bronchodilator FEV1 < 80% predicted and FEV1/FVC ratio <0.7) and gave a 
history of one severe exacerbation in the previous year.. The primary end-points were peak 
FEV1 within 3 hours of drug administration and trough FEV1, both at week 24, and the time to 
the first severe asthma exacerbation during 48 weeks. Baseline characteristics of the 
participants [mean (SD)] were as follows: age, 53 (12) years, ACQ-7 score, 2.6 (0.7), FEV1 
percent predicted after bronchodilation, 62.2 (12.7) and percent of participants with <3 severe 
exacerbations in past year, 80.9%]. In both trials, the improvement in peak and trough FEV1 was 
significantly greater with tiotropium than with placebo. The time to the first severe 
exacerbation was increased by 56 days with tiotropium compared with placebo (282 days vs. 
226 days), with a risk reduction of 21% (hazard ratio, 0.79; p=0.03 in pooled analysis). The total 
number of severe exacerbations per patient-year was slightly reduced with tiotropium (0.53 
tiotropium vs. 0.66 placebo, p=0.046). A consistent improvement in ACQ and AQLQ scores was 
not found in both replicate studies. A Cochrane systematic review (3 trials, 1197 participants) 
evaluated the effects of adding a LAMA (tiotropium) to combination ICS and LABA in adults 
whose asthma was not well controlled by ICS and LABA 22. The review included the two 
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replicate trials described above  21 and one phase III trial in which the primary end-point was 
the number of patients with drug-related adverse events 23. The addition of tiotropium resulted 
in 24% reduction in severe exacerbations (OR 0.76, 95% CI 0.57 to 1.02), although the 
confidence intervals indicated the possibility of no beneficial effect. Small improvements in lung 
function and asthma control were found with tiotropium, but no improvement in asthma 
quality of life score.  
 
2.5 Tiotropium in real-life populations 
 
A retrospective study of 2042 adults with asthma recorded in a United Kingdom primary care 
practice database that were prescribed tiotropium found that in the year after the addition of 
tiotropium compared with the previous year there was a decrease in the percentage of patients 
having at least one exacerbation, defined as an asthma-related hospital emergency department 
attendance or inpatient admission, or acute oral corticosteroid course (37% to 27%, p=0.001) and 
a reduction in the percentage having at least one acute respiratory event, defined as an 
exacerbation or antibiotic prescription with a lower respiratory consultation (58% to 47%, 
p=0.001) 24. Lung function was unchanged, but there was a small increase in short-acting beta2-
agonist use.  
 
2.6 Predictors of efficacy to tiotropium 
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Airway obstruction and acute bronchodilator reversibility predicted a positive FEV1 response to 
tiotropium in adults whose asthma was not well controlled by low-dose ICS and who were not 
taking a LABA 18, 25. In this study, neither gender, body mass index, asthma duration, atopic status, 
serum IgE, sputum eosinophils or fraction of exhaled nitric oxide were predictive 25. In two 
replicate phase III trials that compared the efficacy of tiotropium 5 μg or placebo as an add-on to 
ICS plus a LABA in adults with severe symptomatic asthma 21, a range of  baseline characteristics 
did not predict a beneficial response to tiotropium, including age, gender, race, body mass index, 
disease duration, FEV1 percent predicted, reversibility, serum IgE, blood eosinophils and  B16-
Arg/Arg genotype 26. In 388 patients with asthma that was not controlled by ICSs alone and who 
had a B16-Arg/Arg genotype, tiotropium was non-inferior to salmeterol in the change in PEF 
during 16 weeks of treatment 27.  
 
2.7 Adverse effects of tiotropium 
 
Data on adverse events pooled from seven phase II and III randomized controlled trials of 12 to 
52 weeks’ duration of once-daily tiotropium 5 μg and 2.5 μg (Respimat) versus placebo as add-
on to different background maintenance therapy was reported in 3474 adults with 
symptomatic asthma, of whom 2157 received tiotropium 28. The proportion of participants with 
adverse events was similar between groups. Dry mouth was reported by 1% of the tiotropium 5 
μg daily group, 0.4% of the tiotropium 2.5 μg daily group and 0.5% in the placebo group. 
Cardiac adverse events occurred in 1.4% of patients and were similar between the study 
groups. Serious adverse events were comparable: 5% in the tiotropium 5 μg daily group, 2% in 
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the tiotropium 2.5 μg daily group and 3.3% to 4.9% in the placebo groups. The UK Medicines 
and Healthcare products Regulatory Agency (MHRA) issued a safety update advising prescribers 
to take the risk of cardiovascular side effects into account when prescribing tiotropium 
delivered via Respimat or Handihaler to patients with certain cardiac conditions who were 
excluded from clinical trials of tiotropium including the Investigators in the Tiotropium Safety 
and Performance in Respimat (TIOSPIR) Study 29: recent myocardial infarction < 6 months; any 
unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a 
change in drug therapy in the past year; hospitalisation of heart failure (NYHA Class III or IV) 
within the past year 30. Tiotropium should be used with caution in patients with narrow-angle 
glaucoma, prostatic hyperplasia or bladder-neck obstruction. 
 
2.8 Umeclidinium 
 
A phase II study of the LAMA umeclidinium in combination with the ICS fluticasone furoate 
demonstrated a dose-response improvement in trough FEV1 in adults with asthma compared 
fluticasone furoate alone 31, whereas consistent bronchodilation was not found in adults with 
mild asthma who were not receiving ICS 32. A 52-week phase III parallel group study is 
underway, comparing the efficacy and safety and of the fixed dose combination of the 
fluticasone furoate, umeclidinium and the LABA, vilanterol compared with the fixed dose 
combination of fluticasone furoate and vilanterol in subjects with inadequately controlled 
asthma despite ICS and LABA maintenance therapy (ClinicalTrials.gov Identifier: NCT02924688) 
33 (Table 2).  
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2.9 Glycopyrronium 
 
Several phase III 52-week parallel group trials are underway, comparing the fixed dose 
combination of the LAMA glycopyrronium with an ICS (extrafine beclometasone dipropionate 
or mometasone furoate) and a LABA (formoterol or indacaterol) in patients with uncontrolled 
asthma receiving medium or high dose ICS and LABA (ClinicalTrials.gov Identifiers: 
NCT02676076; NCT02676089; NCT02571777) 33 (Table 2).  
 
3. CRTH2 ANTAGONISTS 
 
The chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) receptor, 
also known as the prostaglandin D2 receptor 2 (DP2), is expressed on Th2 cells, eosinophils, 
basophils, airway epithelial cells and type 2 innate lymphoid cells 29, 30. Prostaglandin D2 
activates the CRTH2 receptor to induce chemotaxis and cell activation. The oral CRTH2 receptor 
antagonists OC000459 and setipiprant both attenuated allergen-induced late asthmatic 
responses 34, 35 and reduced the associated sputum eosinophilia 34. In patients with mild asthma 
not taking ICS, the administration of OC000459 for 4 to 12 weeks produced modest 
improvements in lung function and asthma control 36, particularly in those with a blood 
eosinophilia 36, 37. The oral CRTH2 receptor antagonist BI 671800 administered for 6 weeks to 
patients with mild asthma produced small improvement in FEV1 compared to placebo , but the 
changes were significantly less than those with fluticasone propionate, 440 μg daily 38.  Four 
weeks treatment with the oral CRTH2 antagonist AZD1981 failed to improve lung function in 
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patients with asthma after  ICS withdrawal or while receiving ICS 39. An oral dual antagonist of 
human DP1 and CRTH2 receptors AMG 853, when added  to ICS  treatment, did not improve  
symptoms and lung function or reduce sputum eosinophils in patients with poorly controlled 
moderate to severe asthma 40.  In a phase II trial undertaken in 157 patients with mild to 
moderate allergic asthma, the oral CRTH2 antagonist fevipiprant (QAW039) did not improve 
lung function or asthma control, except in a subgroup with more severe airflow obstruction 41. 
A recent 12-week phase II exploratory trial investigated the efficacy of the fevipiprant 
(QAW039) 225 mg twice per day or placebo in 61 patients with persistent, moderate-to-severe 
asthma and an elevated sputum eosinophil count (≥2%) 42. The main finding was that sputum 
eosinophil percentage (primary end-point) decreased from a geometric mean of 5·4% (95% CI 
3·1 to 9·6) to 1·1% (0·7 to 1·9) in the fevipiprant group (a reduction of 4.5 times from baseline) 
and from 4·6% (2·5 to 8·7) to 3·9% (CI 2·3 to 6·7) in the placebo group (a reduction of 1.3 times 
from baseline group) (difference between groups 3·5 times, 95% CI 1·7 to 7·0; p=0·0014) 42.   
 
In summary, phase II trials of several oral CRTH2 antagonists in mild to severe asthma have 
shown limited efficacy in improving lung function or asthma control, although preliminary 
evidence suggests that blood or airway eosinophilia may predictive a beneficial response to 
these compounds. Phase II trials are underway to examine the effect of the CRTH2 receptor 
antagonist OC000459 on eosinophilic airway inflammation and asthma control in adults with 
severe eosinophilic asthma [ClinicalTrials.gov Identifier: NCT02560610] 33 and in preventing or 
attenuating the symptoms of an asthma exacerbation after experimentally induced rhinovirus 
infection [ClinicalTrials.gov Identifier: NCT02660489] 33. Two replicate 52-week phase III parallel 
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trial are under way to investigate the efficacy and safety of two doses of fevipiprant (QAW039), 
compared with placebo, when added to patients aged 12 years and older with severe asthma 
that is uncontrolled on GINA steps 4 and 5 treatment. The primary end-point is reduction in the 
rate of moderate-to-severe exacerbations in patients with severe asthma and high eosinophil 
counts and in all patients with severe asthma [ClinicalTrials.gov Identifier: NCT02563067 and 
NCT02555683) 33 (Table 2). 
 
4.  PHOSPHODIESTERASE INHIBITORS 
 
Phosphodiesterase (PDE)4 inhibitors have anti-inflammatory effects on effector cells potentially 
relevant to the treatment of asthma 43-45. In a Phase II  allergen challenge study, the oral PDE4 
inhibitor roflumilast attenuated the late phase response and the associated rise in sputum 
eosinophils and neutrophils numbers 46. An overview of nine phase II and phase III placebo-
controlled studies of roflumilast in asthma with a duration of 4 to 24 weeks found a trend for an 
improvement in FEV1, although changes reached statistical significant in only three studies 47. In 
two phase III trials included in the review, the addition of roflumilast 500 μg daily to low doses 
of ICSs [beclomethasone dipropionate (BDP) or fluticasone propionate (FP)] found significant 
improvements in FEV1 (71 ml) compared to BDP 400 μg daily, but the changes were not 
significant compared to FP 250 μg daily. The improvement in FEV1 with roflumilast and BDP 400 
were equivalent to BDP 800 μg daily 47. A phase II cross-over study of roflumilast combined with 
montelukast in 64 patients with uncontrolled asthma despite treatment with medium dose ICS 
and LABA combination produced an improvement in FEV1 (100 ml) at 4 weeks compared to 
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montelukast alone 48. A pooled analysis of one open label and ten phase II and III studies of 
roflumilast at doses of 125, 250, and 500 μg daily for asthma involving 2851 participants 
reported that headache was the most frequent adverse effect with an incidence of 50 and 29.2 
per 100 patients-years in the 500 μg roflumilast and placebo groups respectively 49. Nausea and 
diarrhoea were also often associated with roflumilast use. 
 
Inhaled formulation have been developed that may improve the therapeutic index of PDE4 
inhibitors 50-52. Inhaled PDE4 inhibitors GSK256066 and CHF6001 both inhibit allergen-induced 
late asthmatic responses 53, 54.  An inhaled dual PDE3 and PDE4 inhibitor RPL554 has 
bronchodilator effects and is well tolerated in patients with asthma 55. A preliminary report of a 
Phase II trial of nebulized doses of RPL554 compared to salbutamol and placebo on lung 
function in patients with asthma found that RPL554 caused a dose dependent bronchodilation 
similar to salbutamol, but with fewer side effects 56. 
 
5. CXCR2 ANTAGONISTS 
 
CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts and 
airway smooth and when  activated by ligands such as the chemokines CXCL8 (IL-8) induces 
neutrophil chemotaxis, proteases production, airway goblet cell hyperplasia, collagen 
deposition and airway smooth muscle contraction and  migration 57. Neutrophilic airway 
inflammation is found in some patients with asthma although the role of neutrophils in the 
pathogenesis of asthma is uncertain 58. A phase II study found that the 4-weeks treatment with 
17 
 
CXCR2 antagonist SCH527123 reduced sputum neutrophil percentage by 36.3% in patients with 
severe asthma and sputum neutrophils > 40%. 59. A 26-week phase II randomized controlled 
trial, investigated the efficacy and safety of a CXCR2 antagonist AZD5069 15, or 45 mg oral 
twice daily or matched placebo in 640 participants with severe, uncontrolled persistent asthma 
despite combination treatment with medium-dose or high-dose ICS and LABA. AZD5069 did not 
reduce the rate of severe exacerbations (primary end-point) at any dose despite a dose-
dependent reduction in blood neutrophil counts 60. No phase III clinical trials of CXCR2 
antagonist for asthma are currently registered in the ClinicalTrials.gov website 33. 
 
6. PROTEIN KINASE INHIBITORS 
 
Inhibitors of protein kinases involved in cellular signalling of pro-inflammatory cytokines 
implicated in the pathogenesis of asthma may have a role in the treatment of severe asthma 61-
65. Several p38 mitogen-activated protein kinase (MAPK) inhibitors restore corticosteroid 
sensitivity in peripheral blood mononuclear cells (PBMCs) and alveolar macrophages from 
patients with severe asthma 63, 66. A phase II trial is registered as investigating the efficacy and 
safety of the inhaled p38MAPK inhibitor AZD7624 in corticosteroid resistant asthma 
(ClinicalTrials.gov Identifier: NCT02753764) 33. A specific c-kit tyrosine kinase inhibitor imatinib 
attenuates airway inflammation and remodelling in a murine model of asthma 67, 68 and the 
compound is under development for patients with severe refractory asthma (Phase II trial, 
ClinicalTrials.gov Identifier: NCT01097694) 33. A tyrosine kinase inhibitor masitinib improved 
asthma control in patients with severe corticosteroid-dependent asthma 69. A phase III clinical 
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trial of masitinib is registered as underway in patients with severe asthma treated with oral 
corticosteroids (ClinicalTrials.gov Identifier: NCT01449162; Last verified 2012) 33 (Table 2).  
 
7. SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS 
 
Non-steroidal selective glucocorticoid receptor agonists and modulators are in development 
with the aim of improving the therapeutic ratio of corticosteroids by dissociating 
transactivation, which is associated with the adverse effects of corticosteroids, from the 
beneficial effect through  inhibition of pro-inflammatory gene transcription (transrepression) 70-
72. This concept has been challenged as it does not account for the observations that the 
production of anti-inflammatory proteins may have a more important role in resolution of 
inflammation than previously considered 73.  Only a small number of these molecules have been 
tested in asthma. An inhaled glucocorticoid receptor agonist GW870086 attenuated adenosine 
induced bronchoconstriction in asthma 74,  although chronic dosing did not improve lung 
function or reduces rescue medication use in patients with mild to moderate asthma 75. A 
nonsteroidal glucocorticoid receptor agonist AZD5423 reduced the fall in FEV1 and sputum 
eosinophilia during the late asthmatic response induced by allergen challenge 76. The efficacy 
and safety of a nonsteroidal glucocorticoid receptor agonist AZD7594 has undergone phase II 
clinical evaluation in patients with mild to moderate asthma (ClinicalTrials.gov Identifier: 
NCT02479412) 33, although to date, results of the study have not been published. 
 
8.  MACROLIDES 
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Macrolides possess pharmacological properties that are potentially relevant to the treatment of 
asthma, such as antibacterial and antiviral activity 77, 78.  Anti-inflammatory properties of 
macrolides  include inhibition of nuclear factor-κB,  reduction in neutrophil migration and/or 
function 79-83 and attenuation of tumor necrosis factor  and interleukin-17 immune responses 84. 
Macrolides also restore corticosteroid sensitivity through phosphoinositide 3-kinase (PI3K) 
pathway inhibition 85-87. The macrolides most commonly used in clinical trials in asthma include 
azithromycin, clarithromycin, roxithromycin and troleandomycin 88. Novel analogues of macrolides 
have been developed, such as solithromycin (CEM-101) that has enhanced anti-inflammatory 
properties compared to current macrolides, 83, 86, the non-antibiotic azithromycin derivative 
CSY0073  that lacks anti-bacterial properties 89 and the oleandomycin derivative MAC5 that has 
enhanced ant-viral activity 90. No clinical trials of macrolide analogues in asthma are currently listed 
in the clintrials.gov. website 33. 
 
A Cochrane systematic review (23 trials, 1513 participants) evaluated the effects of macrolides for 
managing asthma 88. Macrolides did not improve most clinical outcomes compared to placebo 
including exacerbations (OR 0.82, 95% CI 0.43 to 1.57), symptoms and asthma quality of life, 
although there was a modest increase in FEV1 (80 ml, 95% CI 20 to 140). Two studies suggested 
that macrolides may have an oral corticosteroid sparing effect. Macrolides have been investigated 
in non-eosinophilic asthma, suggesting a beneficial effect in never and former smokers with 
asthma 91, but not in smokers with asthma 92. A randomized controlled trial investigated low-dose 
azithromycin or placebo for 6 months as add-on treatment to combination therapy of ICS and LABA 
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in patients with exacerbation-prone severe asthma 91. Azithromycin did not improve the primary 
end-points of the number of severe exacerbations and lower respiratory tract infections. 
Azithromycin reduced the primary endpoints in a predefined subgroup with non-eosinophilic 
severe asthma (blood eosinophilia ≤200/µl). In a clinical  trial in smokers with mild to moderate 
asthma, azithromycin 250 mg per day for 12 weeks resulted in no  improvements in morning PEF, 
ACQ score, AQLQ score and methacholine PC20 compared to placebo 92.  Common adverse effects 
of macrolides are nausea and diarrhoea. Drug inhibitors or inducers of the cytochrome P450 3A4 
(CYP3A) enzyme that metabolizes macrolides may cause serious interactions. Macrolides prolong 
the QTc interval that in susceptible individuals can cause ventricular fibrillation and sudden death. 
Long-term treatment increases the risk of the development of  microbial resistance 79.  
  
9. STATINS 
 
The pleiotropic immunomodulatory properties of statins  93 and their ability to restore 
corticosteroid sensitivity 94, 95  suggest that statins may improve clinical outcomes in asthma 93, 96-99. 
A small number of randomized controlled trials in adults with mild to moderate asthma found that 
short-term statin treatment did not improve lung function or symptom control in non-smokers 
with asthma 100. In smokers with asthma, atorvastatin treatment resulted in a small improvement 
in asthma quality of life and symptoms that were associated with reductions in several sputum 
cytokines, chemokines and growth factors concentrations unresponsive to ICS treatment 101, 102. 
Several observation studies report that statin use in asthma is associated with a reduced risk of 
asthma-related emergency department visits, oral corticosteroid dispensing or hospital admissions 
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100. Statins treatment in asthma may have modest local anti-inflammatory effects in the airways 100. 
A 12-week phase II study is examining the effects of simvastatin on airway inflammation, lung 
function and exacerbations in patients with severe asthma taking ICS and LABA (ClinicalTrials.gov 
Identifier: NCT02433535) 33.  
. 
10.  ULTRA-LOW DOSE THEOPHYLLINE 
 
Low dose theophylline restores corticosteroid sensitivity in-vitro, possibly by increasing histone 
deacetylase (HDAC)-2 activity, which is suppressed in severe asthma and in smokers with 
asthma 103, 104. Theophylline inhibits oxidative stress dependent PI3K-δ activation and restores 
corticosteroid sensitivity in PBMCs from patients with COPD 104. A clinical trial of ultra-low dose 
theophylline, titrated to provide a ‘sub-therapeutic’ concentration, when added to inhaled  
beclometasone in smokers with asthma, resulted in increased efficacy as measured by lung 
function compared to inhaled beclometasone alone suggesting the restoration of corticosteroid 
sensitivity in those treated with the combination 105.  Clinical trials to date have not investigated 
the therapeutic effects of a combination of ultra-low dose of theophylline with ICS in severe 
asthma. The development of fixed combination of ultra-low dose theophylline with fluticasone 
propionate (SKP-2075) in a dry powder inhaler for the treatment of smokers with asthma and 
COPD is currently on hold 106. 
 
CONCLUSION  
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The LAMA tiotropium is the only small molecule drug approved for the maintenance treatment 
of adults and adolescents with asthma in recent years. Clinical trials of tiotropium in asthma 
report improvements in lung function and reductions in exacerbations in patients taking ICS 
alone and the combination of medium to high dose ICS and LABA. The LAMAS umeclidinium 
and glycopyrronium are under development in fixed dose combination with ICS and LABA in 
patients with uncontrolled severe asthma. Several novel small molecule drugs are under clinical 
development for asthma, although none are approved for use in clinical practice. Short-term 
phase II clinical trials of the CRTH2 receptor antagonists AMG 853, AZD1981, BI 671800, 
OC000459 and fevipiprant (QAW039) in chronic asthma have produced little or no 
improvements in symptoms and lung function, except in eosinophilic subgroups. Based on 
evidence suggesting that blood and/or airway eosinophilia may predictive a beneficial response 
to these compounds, the CRTH2 receptor antagonist fevipiprant (QAW039) is being 
investigated in two replicate 52-week phase III parallel trial in patients with severe asthma, 
including a subgroup with high eosinophil counts, and a phase II trial is underway to examine 
the effect of OC000459 on eosinophilic airway inflammation and asthma control in adults with 
severe eosinophilic asthma. The PDE4 inhibitor roflumilast produces modest improvements in 
FEV1 in some studies, including when added to low dose BDP and when compared to the 
addition of montelukast in patients taking ICS and LABA. The main adverse effects are 
headache, nausea and diarrhea. An inhaled dual PDE3 and PDE4 inhibitor RPL554 has acute 
bronchodilator effects comparable to inhaled salbutamol. A phase II trial of the CXCR2 
antagonist AZD5069 adults with severe, uncontrolled persistent asthma despite combination 
treatment with medium-dose or high-dose ICS and LABA produced no reduction in severe 
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exacerbations despite a reduction in blood neutrophil counts. Several protein kinase inhibitors 
are under investigation including the inhaled p38MAPK inhibitor AZD7624 in corticosteroid 
resistant asthma, the specific c-kit tyrosine kinase inhibitor imatinib in severe refractory 
asthma, and the tyrosine kinase inhibitor masitinib in severe asthma treated with oral 
corticosteroids. The efficacy and safety of a nonsteroidal glucocorticoid receptor agonist 
AZD7594 has undergone phase II clinical evaluation in patients with mild to moderate asthma, 
although to date, results have not been published. Exploratory clinical studies of ‘off-label’ use 
of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic 
severe asthma and statins and ultra-low dose theophylline may benefit smokers with asthma. 
 
EXPERT OPINION  
 
Surveys of adults and adolescents with asthma report that many people have poorly controlled 
symptoms despite long-term treatment with an ICS alone or combined with a LABA. For many 
of these individuals there is an unmet need for improved therapies, particularly for those with 
severe asthma. Despite the clinical development of many novel small molecule compounds, 
tiotropium is the only drug approved for the treatment of adults and adolescents with asthma 
in recent years. The beneficial effects of tiotropium are improved FEV1 and a modest reduction 
in exacerbations when added to ICS or the combination of ICS and LABA.  At step 4, there is a 
lack of studies comparing the effectiveness of tiotropium with other add-on therapies, such as 
leukotriene antagonists and theophylline. The participants recruited to clinical trials of 
tiotropium may not be representative of real-life populations of asthma, since current smokers, 
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former smokers with greater than a 10 pack-years and older people aged >75 years were 
excluded 21. Fixed dose combinations of LAMAs, umeclidinium or glycopyrronium, with ICS and 
LABA are undergoing evaluation in patients with uncontrolled severe asthma and these 
combination treatments are likely to have similar clinical benefits to those found with the 
addition of tiotropium in this patient group. Novel small molecules drugs, such as the CRTH2 
receptor antagonist fevipiprant (QAW039), the PDE4 inhibitor roflumilast, several protein kinase 
inhibitors and the nonsteroidal glucocorticoid receptor agonist AZD7594 are under 
development for asthma, although only a small number of phase III trials are registered on the 
clinicaltrials.gov website and none of these drugs are currently approved for use in clinical 
practice. Several drugs licensed for the treatment of medical conditions other than asthma 
have been investigated for their efficacy in asthma. The ‘off-label’ use of licensed drugs, such as 
macrolides, statin and ultralow-dose theophylline are not established for the treatment of 
asthma and funding for large clinical trials of these drugs in asthma is likely to be difficult. Of 
the small molecule drugs under development for asthma, the fixed dose combinations of 
LAMAs, umeclidinium or glycopyrronium, with ICS and LABA are the ones most likely to be 
marketed for the treatment of severe asthma in the next few years.  
 
Several monoclonal antibodies are approved for the treatment of asthma, including anti-IgE 
(omalizumab) and anti-IL-5 (mepolizumab, reslizumab) and others are under development 107.  
An important aim in the future will be to assess if novel small molecule drugs can replace or 
complement the use of one or more of the monoclonal antibodies therapies approved or under 
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development for asthma, possibly at a reduced cost. For example, could an effective CRTH2 
antagonist replace monoclonal antibody therapy for severe eosinophilic asthma? 
 
The ideal properties of a new small molecule drug for asthma should include once daily dosing, 
an impact on reducing exacerbations and oral corticosteroid sparing actions. The assessment of 
new therapies should involve studies that compare novel drugs with current add-on therapies 
and that reflect real life populations of asthma. To better achieve the goal of developing 
effective novel small molecule drugs for asthma will require greater understanding of 
mechanisms of disease and the different phenotypes and endotypes of asthma. International 
collaborative programmes of research investigating pathogenic mechanism of severe asthma 
such as the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-
BOPRED) study 108, 109 and the UK Refractory Asthma Stratification Programme (RASP-UK) 110 are 
designed to identify new phenotypes/endotypes and treatment targets that will hopefully 
identify new approaches to the treatment of asthma including small molecules drugs that 
demonstrate effectiveness that would warrant approval for use in clinical practice. 
  
ARTICLE HIGHLIGHTS BOX  
 
 The long-acting muscarinic antagonist (LAMA) tiotropium is the only small molecule drug 
approved for the maintenance treatment of adults and adolescents with asthma in recent 
years. Clinical trials of tiotropium in asthma report improvements in lung function and 
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modest reductions in exacerbations in patients taking ICS alone and the combination of 
medium to high dose ICS and LABA.  
 
 The LAMAs umeclidinium and glycopyrronium are under development in fixed dose 
combination with ICS and LABA in patients with uncontrolled severe asthma.  
 
 Novel small molecules drugs, such as the CRTH2 receptor antagonist fevipiprant (QAW039), 
the PDE4 inhibitor roflumilast, several protein kinase inhibitors and the nonsteroidal 
glucocorticoid receptor agonist AZD7594 are under development for asthma, although only 
a small number of phase III studies are registered on the clinicaltrials.gov website and none 
of these drugs are currently approved for use in clinical practice. 
 
 Exploratory clinical studies of ‘off-label’ use of licensed drugs suggest that macrolides show 
efficacy in non-smokers with non-eosinophilic severe asthma and statins and ultralow-dose 
theophylline may benefit smokers with asthma, although the effectiveness of these drugs in 
clinical practice is not established.  
 
 To better achieve the goal of developing effective novel small molecule drugs for asthma 
will require greater understanding of mechanisms of disease and the different phenotypes 
and endotypes of asthma. 
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TABLE 1: NEW AND DEVELOPING NON-ADRENORECEPTOR SMALL MOLECULE DRUGS FOR THE 
TREATMENT OF ASTHMA 
 
Long-acting muscarinic antagonists (LAMA) 
CRTH2 antagonists 
Phosphodiesterase (PDE) inhibitors 
PDE4 inhibitors  
Dual PDE3 and PDE4 inhibitors  
Protein kinase inhibitors 
p38 Mitogen-activated protein kinase (MAPK) inhibitor 
Tyrosine kinase inhibitor 
CXCR2 antagonists  
Selective glucocorticoid receptor modulators 
Macrolides 
Statins  
Ultra-low dose theophylline 
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TABLE 2: PHASE III CLINICAL TRIALS OF NON-ADRENOCEPTOR SMALL MOLECULE DRUGS AS ADD-
ON THERAPIES UNDERWAY IN ASTHMA* 
Small molecule drug and study 
title 
ClinicalTrials.gov 
Identifier: 
Status, 
estimated 
enrolment 
End-points Estimated 
Completion 
Date 
Sponsor 
LAMA: Umeclidinium 
A 52 week, parallel group study, 
comparing the efficacy, safety and 
tolerability of the fixed dose 
combination of fluticasone furoate 
(FF) + umeclidinium bromide 
UMEC) + vilanterol (VI) 
(FF/UMEC/VI) with the fixed dose 
combination of FF/VI in subjects 
with inadequately controlled 
asthma 
 
NCT02924688 
 
Recruiting, 
n=2250 
 
Primary: trough FEV1 
at week 24 
Secondary: include 
the number of 
moderate and severe 
exacerbations up to 
week 52. 
 
February 
2018 
 
GlaxoSmithKline 
LAMA: Glycopyrronium 
A 52-week, parallel group trial 
comparing a fixed dose 
combination of extrafine 
beclometasone dipropionate 100 
µg plus formoterol 6 µg plus 
glycopyrronium 12.5 µg (CHF 5993) 
with fixed dose combination of 
extrafine beclometasone 
dipropionate 100 µg plus 
formoterol 6 µg (CHF 1535) in 
patients with uncontrolled asthma 
receiving medium dose ICS and 
LABA - TRIple in asthMA With 
uncontRolled pAtient on Medium 
streNgth of ICS + LABA (TRIMARAN) 
 
NCT02676076 
 
 
Recruiting, 
n=1148 
 
Primary: trough FEV1 
at week 26 and 
reduction of 
moderate and severe 
asthma exacerbations 
rate up to week 52 
 
 
June 2018   
 
Chiesi  
A 52-week, parallel trial comparing 
a fixed dose combination of 
extrafine beclometasone 
dipropionate 200 µg plus 
formoterol 6 µg plus 
glycopyrronium 12.5 µg (CHF 5993) 
with fixed dose combination of 
extrafine beclometasone 
dipropionate 200 µg plus 
formoterol 6 µg (CHF 1535) alone 
or plus open-label tiotropium 2.5 
µg Respimat® in patients with 
uncontrolled asthma receiving high 
dose ICS and LABA - TRIple in 
Asthma hiGh strenGth vErsus 
NCT02676089 Recruiting, 
n=1435 
Primary: trough FEV1 
at week 26 and 
reduction of 
moderate and severe 
asthma exacerbations 
rate up to week 52 
 
July 2018 Chiesi  
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*Information obtained from ClinicalTrials.gov website 33 
Abbreviations: LAMA, long-acting muscarinic antagonist; FEV1, forced expiratory volume in 1 second 
 
 
 
Ics/Laba hs and tiotRopium 
(TRIGGER)). 
A 52-week, parallel group trial 
comparing the efficacy and safety 
of two different doses of a fixed 
dose combination of indacaterol, 
mometasone furoate and 
glycopyrronium (QVM149 
150/50/80 μg and QVM149 
150/50/160 μg) over two 
respective doses of indacaterol and 
mometasone furoate (QMF149 
150/160 μg and QMF149 150/320 
μg) in patients with poorly 
controlled asthma receiving 
medium or high doses of ICS and 
LABA 
NCT02571777 Recruiting, n= 
3155 
Primary: trough FEV1 
at week 26 
Secondary: include 
asthma exacerbation 
over 52 weeks 
 
October 
2018   
Novartis 
CRTH2 receptor antagonist: 
fevipiprant (QAW039) 
Two replicate 52-week, 
multicenter, randomized, double-
blind, placebo-controlled studies to 
assess the efficacy and safety of 
fevipiprant (QAW039) when added 
to existing asthma therapy in 
patients with uncontrolled severe 
asthma 
 
 
NCT02563067 and 
NCT02555683 
 
 
 
 
 
 
Recruiting, 
n=846 each 
study 
 
 
Primary:  Moderate-
to-severe asthma 
exacerbations in 
patients with severe 
asthma and high 
eosinophil counts and 
in all patients with 
severe asthma 
 
 
November 
2018 
 
 
Novartis 
Protein kinase inhibitor:  tyrosine 
kinase inhibitor masitinib 
A 36-week study to compare the 
efficacy and safety of masitinib to 
placebo in treatment of patients 
with severe persistent asthma 
treated with oral corticosteroids 
 
 
NCT01449162 
 
 
Recruitment 
status 
unknown, 
n=300 
 
 
Primary:  asthma 
exacerbation rate at 
week 36 
 
 
Unknown 
(status has 
not been 
verified in 
more than 
two years) 
 
 
AB Science 
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FIGURE LEGEND 
 
Figure 1: Stepwise approach to control symptoms and minimize future risk 
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